Reboxetine (Vestra)

01/01/2009 - "The study revealed that reboxetine may be beneficial in treatment of ADHD. "
07/01/2009 - "At the end of 8 weeks, both reboxetine and MPH treatment regimens resulted in significant improvement in ADHD symptoms. "
11/01/2010 - "The main aim of this study is to evaluate the efficacy of reboxetine, a specific noradrenergic reuptake inhibitor, in adults with attention-deficit/hyperactivity disorder (ADHD). "
11/01/2010 - "Reboxetine could be used and tolerated as an effective treatment for adults with ADHD."
01/01/2001 - "Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder."

09/01/2004 - "Our results suggest that the adjunctive use of reboxetine may be an effective treatment for depressive and negative symptoms in schizophrenia."
01/01/2020 - "Results of previous studies on the safety and efficacy of adjunctive reboxetine for schizophrenia have been inconsistent. "
01/01/2020 - "Adjunctive Reboxetine for Schizophrenia: Meta-analysis of Randomized Double-blind, Placebo-controlled Trials."
10/01/2015 - "Previous studies regarding the useful effects of reboxetine on deficit symptoms of schizophrenia have resulted in inconsistent results. "
01/25/2018 - "Our results provide tentative very low quality evidence that compared to placebo, NRIs (specifically reboxetine) may have a benefit on the negative symptoms of schizophrenia. "

02/01/2000 - "This study demonstrated that reboxetine is significantly more effective than placebo in the treatment of hospitalized patients with severe major depressive disorder and is well tolerated."
01/01/2007 - "In this prospective 12-week open-label study, we evaluated the effectiveness of the addition of reboxetine to 141 outpatients diagnosed with major depressive disorder, according to DSM-IV-TR criteria, who were partial responders or non-responders over a period of 6 weeks, to previous treatment in monotherapy with SSRI. "
04/01/2003 - "An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder."
04/01/2003 - "Trial I included patients receiving racemic reboxetine as 6-month monotherapy for treatment of major depressive disorder. "
02/01/2000 - "Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder."

01/01/2002 - "At last assessment, there was a significant reduction in the mean number of panic attacks (range, 9.3-1.2) and phobic symptoms (range, 8.1-3.2) in the reboxetine group compared with the placebo group (ranges, 8.5-5.8 and 7.7-5.2, respectively; p < .05). "
10/01/2002 - "Reboxetine appears to be effective in the treatment of SSRI-refractory panic disorder patients and warrants further clinical investigation."
10/01/2002 - "The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study."
10/01/2002 - "In this 6-week, open-label study, 29 adult outpatients with panic disorder who had previously failed to respond to SSRI treatment received reboxetine 2 mg/day, titrated to a maximum of 8 mg/day over the first 10 days. "
01/01/2002 - "Reboxetine was effective and well tolerated in the treatment of panic disorder."

08/01/2002 - "Compared with placebo, the proportion of patients with improvement on the HAM-D agitation item and the HAM-D anxiety and insomnia factors from baseline was significantly greater with reboxetine at most assessment intervals. "
08/01/2002 - "Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials."
10/11/2023 - "Eleven had higher risks for insomnia, reboxetine ranked the top (OR = 3.47; 95% CI: 2.77 to 4.36). "
08/01/2002 - "Although reboxetine was associated with a significant (p < 0.05) increase in treatment-emergent insomnia reported as an adverse effect during the first week of treatment, very few reports of insomnia were made at subsequent evaluations. "
08/01/2002 - "In addition, the incidence of treatment-emergent agitation, anxiety, and insomnia side effects with reboxetine were examined. "